442
IMMUNOREACT 3: PERITUMORAL IMMUNE MICROENVIRONMENT MARKERS AS PREDICTORS OF RECURRENCE AFTER ADJUVANT THERAPY IN LOCALLY ADVANCED RECTAL CANCER
Date
May 19, 2024
Tracks
Related Products
EFFECT OF SCREENING STRATEGIES ON THE NATURAL HISTORY OF IBD-RELATED AND SPORADIC COLORECTAL CANCER
BACKGROUND: Inflammatory bowel disease encompasses two types of idiopathic intestinal disease, ulcerative colitis (UC) and Crohn's disease (CD) that are differentiated by their location and depth of involvement in the bowel wall…
RANDOMIZED CONTROLLED TRIAL ON ORAL ADMINISTRATION OF LACTOBACILLUS CASEI DG FOR 8 WEEKS AFTER ILEOSTOMY CLOSURE (MICROBIOTA AND IMMUNE (MICROENVIRONMENT IN POUCHITIS.-MEP1- NCT03136419).
BACKGROUND: Around 20-25% of ulcerative colitis patients undergo restorative proctocolectomy with ileal pouch-anal anastomosis. Pouchitis is an idiopathic inflammatory disease that may occur in ileal pouches, and it can lead to ileal pouch failure…
IMMUNOREACT 9: METACHRONOUS RECTAL CANCER ARE FREQUENTLY FROM PREVIOUS RECTAL OR SIGMOID CANCER AND HAVE A LOW INFILTRATION OF CD8+ T CELLS
Socioeconomic status (SES) has proven significant impact on colorectal cancer (CRC) outcomes. Lower SES has correlated with increased comorbidities, risk of postoperative complications, and inadequate adherence to treatment guidelines…
IMMUNOREACT 13: IMMUNE SURVEILLANCE MARKERS IN THE CLINICAL MANAGEMENT OF STAGE II RECTAL CANCER
BACKGROUND Stage II colorectal cancer should undergo adjuvant therapy only in the presence of risk factors and vascular, lymphatic, and perineural invasion (VELIPI) are risk factors for recurrence after surgery…